Answers are grounded in this paper and cite their sources.
Analysis reveals CCS as a prognostic biomarker for colorectal cancer, suggesting its potential as a therapeutic target.
Background Targeting Cu transport proteins is an innovative therapeutic approach for combating cancer. However, the mechanisms underlying the malignant potential of Cu transport proteins remain largely unknown. To address this issue, we focused on the oncogenic potential of copper chaperones for superoxide dismutase (CCS) in colorectal cancer (CRC). Methods We investigated the association between the prognosis and the copper transport protein, CCS, using clinical samples. The function of CCS was analyzed to assess the proliferation and migration potential of CRC cells. Results Univariate and multivariate analyses revealed that CCS was an independent prognostic factor for disease‐free survival and overall survival. CCS is closely related to the malignant potential of CRC, which includes proliferation, migration, and the MEK–ERK pathway. Conclusions Thus, CCS is a valuable biomarker and therapeutic target for CRC.
No takes yet. Share an insight, caveat, or question.
Takiguchi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: